Review findings
1 finding(s) · status completed · 2026-06-14 20:33
Review before activation. Approving creates a source-backed record (asset, dosing reference, or evidence claim). Rejected findings are discarded. Findings you have not approved never reach the Clinical Assistant or protocol builder.
Candidate assets
1
- LL-37conf 90%pending
LL-37 is the only human cathelicidin-derived antimicrobial peptide and a central effector of innate immunity.